Amgen's Uplizna succeeds in study for muscle-weakening Analysts say data from another experimental drug not 'competitive' Shares fall 2% in extended trading on mixed datasets Sept 24 (Reuters) - Amgen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results